A case report of euglycemic ketoacidosis due to dapagliflozin treatment
Open Access
- 7 March 2021
- journal article
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 3 (Supplement), 85-86
- https://doi.org/10.46310/tjim.877156
Abstract
Diabetic ketoacidosis (DKA) is a leading cause of mortality and morbidity in type 2 diabetic patients. Sodium-glucose co-transporter (SGLT-2) inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose. The Food and Drug Administration issued a warning in May 2015 notifying that patients using this class of anti-diabetic drugs may develop DKA. Risk factors for DKA development among patients who take SGLT-2 inhibitors include carbohydrate intake/starvation or acute illness. In the current report, we aimed to present a case of euglycemic DKA using dapagliflozin treatment.Keywords
This publication has 7 references indexed in Scilit:
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021Diabetes Care, 2020
- Newer Perspectives of Mechanisms for Euglycemic Diabetic KetoacidosisInternational Journal of Endocrinology, 2018
- Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 InhibitorThe New England Journal of Medicine, 2017
- Guidelines for management of diabetic ketoacidosis: time to revise?The Lancet Diabetes & Endocrinology, 2017
- SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary LiteraturePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2017
- SGLT2 Inhibitors May Predispose to KetoacidosisJournal of Clinical Endocrinology & Metabolism, 2015
- SGLT2 inhibition — a novel strategy for diabetes treatmentNature Reviews Drug Discovery, 2010